Emergent BioSolutions (EBS) Assets Average (2011 - 2026)
Emergent BioSolutions (EBS) posted quarterly Assets Average of $1.3 billion for Q1 2026, down 6.28% year-over-year from $1.4 billion in Q1 2025, and down 5.06% quarter-over-quarter from $1.4 billion in Q4 2025.
Emergent BioSolutions (EBS) Assets Average (2011 - 2026) Analysis & Trends
Emergent BioSolutions' Assets Average history runs 16 years deep, the most recent figure standing at $1.3 billion for Q1 2026.
- In Q1 2026, Assets Average fell 6.28% year-over-year to $1.3 billion; the TTM figure through Mar 2026 stood at $1.3 billion (down 6.28% YoY), while the FY2025 annual figure was $1.4 billion, down 15.71% from the prior year.
- Assets Average for Q1 2026 stood at $1.3 billion, down from $1.4 billion in the prior quarter.
- The five-year high for Assets Average was $3.1 billion in Q1 2023, with the low at $1.3 billion in Q1 2026.
- The 5-year median for Assets Average is $1.8 billion (2024), against an average of $2.0 billion.
- The sharpest annual moves came in 2023 and 2024: Assets Average advanced 6.59% in 2023, then tumbled 40.7% in 2024.
- Emergent BioSolutions' Assets Average stood at $3.0 billion in 2022, then sank by 38.7% to $1.9 billion in 2023, then slipped by 22.84% to $1.4 billion in 2024, then retreated by 3.07% to $1.4 billion in 2025, then retreated by 5.06% to $1.3 billion in 2026.
- Business Quant data shows EBS's Assets Average at $1.3 billion in Q1 2026, $1.4 billion in Q4 2025, and $1.4 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 43.72 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 39.95 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 15.12 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 98.59 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 6.97 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 35.94 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 5.13 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 13.39 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 5.97 Bn |
| 10 | Emergent BioSolutions | 251.81 Mn | 110.91 Mn | 137.20 Mn | 1.22 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.22 Bn |
| Mar 31, 2026 | 1.32 Bn |
| Dec 31, 2025 | 1.39 Bn |
| Sep 30, 2025 | 1.44 Bn |
| Jun 30, 2025 | 1.42 Bn |
| Mar 31, 2025 | 1.41 Bn |
| Dec 31, 2024 | 1.43 Bn |
| Sep 30, 2024 | 1.50 Bn |
| Jun 30, 2024 | 1.66 Bn |
| Mar 31, 2024 | 1.81 Bn |
| Dec 31, 2023 | 1.86 Bn |
| Sep 30, 2023 | 2.04 Bn |
| Jun 30, 2023 | 2.56 Bn |
| Mar 31, 2023 | 3.06 Bn |
| Dec 31, 2022 | 3.03 Bn |
| Sep 30, 2022 | 2.82 Bn |
| Jun 30, 2022 | 2.76 Bn |
| Mar 31, 2022 | 2.87 Bn |
| Dec 31, 2021 | 2.91 Bn |
| Sep 30, 2021 | 2.89 Bn |